PRTN3 and rheumatoid arthritis: In the ADJUST study, abatacept demonstrated good efficacy in patients with very early RA, including ACPA+ patients with undifferentiated arthritis, delaying onset of RA when compared with placebo, and promoting sustained remission rates and reduced radiographic progression, even after therapy is withdrawn [16].